You are here

Immunotherapy Candidate CV-301 Shows Promise in Colorectal Cancer

Treated patients have significantly better survival versus matched controls (May 29)

Promising data have been reported from a phase II trial of the cancer immunotherapy candidate CV-301 (Bavarian Nordic) in patients with resected metastatic colorectal cancer. The new findings were published in the Annals of Surgery.

In a study conducted at Duke University, 74 patients who were disease-free after surgical resection of metastatic colon cancer received chemotherapy followed by immunotherapy with CV-301 (formerly PANVAC-VF), either as CV-301–modified dendritic cells or in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). The overall survival of the CV-301–treated patients was significantly longer (P

CV-301 (CEA-MUC-1-TRICOM) is an immunotherapy candidate for the treatment of multiple cancers. It originates from the same poxvirus platform as Prostvac (Bavarian Nordic), a therapeutic cancer vaccine in phase III clinical development.

Both CV-301 and Prostvac are prime-boost vaccines that combine two different poxviruses (vaccinia and fowlpox). Collectively, these two product candidates, along with earlier generations of these vaccines, have been the subject of more than 30 clinical trials involving more than 1,100 patients with prostate, breast, lung, colorectal, gastric, pancreatic, ovarian, and other cancers.

While Prostvac incorporates a single antigen that is over-expressed in prostate cancer (prostate-specific antigen [PSA]), CV-301 incorporates two antigens (carcinoembryonic antigen [CEA] and epithelial tumor antigen MUC-1), which are over-expressed in other major cancers, including breast and colon cancers.

Source: Bavarian Nordic; May 29, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation